Back

Arcturus shares rise 6.54% after ARCT-810 Phase 2 data and LUNAR 2.0 launch

Verifying
  • Arcturus reported interim Phase 2 findings for its investigational OTC deficiency treatment ARCT-810.
  • Shares rose 6.54% to $14.17 at publication, according to Benzinga Pro data.
  • Arcturus plans to dose patients aged 12 and older with ARCT-2601 by year-end.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.